Literature DB >> 2378787

Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects.

J H Schellens1, J H van der Wart, D D Breimer.   

Abstract

1. In a phenotyped panel of healthy subjects correlations were studied between the oxidation of mephenytoin, phenytoin, methylphenytoin and phenobarbitone, with respect to the formation of their 4-hydroxy metabolites (OH-). 2. On different occasions phenotyped extensive metabolizers (EM; n = 16) and poor metabolizers (PM; n = 4) of mephenytoin received phenytoin (100 mg), methylphenytoin (100 mg) and phenobarbitone (50 mg) and urine was collected up to 24 h. The excreted 4-hydroxy metabolites of all compounds were measured by h.p.l.c. 3. Urinary recovery of OH-phenytoin was 31.0 +/- 11.7%, of OH-methylphenytoin 3.4 +/- 2.7% and of OH-phenobarbitone 1.4 +/- 1.2%. No correlation was found between the recovery of OH-mephenytoin and OH-phenytoin. A subject who produced virtually no OH-phenytoin was an EM of mephenytoin, confirming a dissociation of mephenytoin polymorphism and phenytoin hydroxylation. 4. The correlation coefficient for OH-mephenytoin and OH-methylphenytoin recovery was 0.71 (Spearman rank, P = 0.002). The PMs of mephenytoin excreted the least amount of OH-methylphenytoin, suggesting a cosegregation of the 4-hydroxylation pathways. No correlation was found between the urinary recovery of OH-phenobarbitone and that of the other 4-hydroxy metabolites.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2378787      PMCID: PMC1380168          DOI: 10.1111/j.1365-2125.1990.tb03687.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  INSUFFICIENT PARAPHYDROXYLATION AS A CAUSE OF DIPHENYLHYDANTOIN TOXICITY.

Authors:  H KUTT; M WOLK; R SCHERMAN; F MCDOWELL
Journal:  Neurology       Date:  1964-06       Impact factor: 9.910

2.  Impairment of phenytoin parahydroxylation as a cause of severe intoxication.

Authors:  F A de Wolff; P Vermeij; M D Ferrari; O J Buruma; D D Breimer
Journal:  Ther Drug Monit       Date:  1983-06       Impact factor: 3.681

3.  Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man.

Authors:  A Küpfer; P V Desmond; S Schenker; R A Branch
Journal:  J Pharmacol Exp Ther       Date:  1982-06       Impact factor: 4.030

4.  Inheritance of phenytoin hypometabolism: a kinetic study of one family.

Authors:  M R Vasko; R D Bell; D D Daly; C E Pippenger
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

5.  Stereoselective metabolism of mephenytoin in man.

Authors:  A Küpfer; R K Roberts; S Schenker; R A Branch
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

6.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

Review 7.  Plasma level monitoring of anticonvulsants.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

8.  Sparteine oxidation by the human liver: absence of inhibition by mephenytoin.

Authors:  M Jurima; T Inaba; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1984-03       Impact factor: 6.875

Review 9.  Clinical pharmacokinetics of phenytoin.

Authors:  A Richens
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

10.  A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin.

Authors:  A Küpfer; G M Brilis; J T Watson; T M Harris
Journal:  Drug Metab Dispos       Date:  1980 Jan-Feb       Impact factor: 3.922

View more
  2 in total

Review 1.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 2.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.